See more : Grindwell Norton Limited (GRINDWELL.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Mosaic ImmunoEngineering Inc. (CPMV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mosaic ImmunoEngineering Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SolTech Energy Sweden AB (publ) (SOLT.ST) Income Statement Analysis – Financial Results
- Powered Brands (POWRU) Income Statement Analysis – Financial Results
- BP p.l.c. (BPE.DE) Income Statement Analysis – Financial Results
- Crazy Woman Creek Bancorp Incorporated (CRZY) Income Statement Analysis – Financial Results
- Optimum Interactive USA Ltd. (OPTL) Income Statement Analysis – Financial Results
Mosaic ImmunoEngineering Inc. (CPMV)
About Mosaic ImmunoEngineering Inc.
Mosaic ImmunoEngineering Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. It offers MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in mice, dogs, and humans. The company was founded in 2020 and is based in Novato, California.
| Metric | 2022 | 2021 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 468.68K | 567.93K | 5.35M | 3.71M | 638.78K | 10.31M | 2.98M | 76.42K | 123.90K | 358.81K | 337.38K | 716.96K | 1.13M | 1.90M | 1.85M | 30.46K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.80M | 4.20M | 3.09M | 1.51M | 319.37K | 103.35K | 0.00 | 10.47K | 18.66K | 393.98K | 544.32K | 357.61K | 711.20K | 1.16M | 1.00M | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.33M | -3.63M | 2.27M | 2.20M | 319.41K | 10.21M | 2.98M | 65.95K | 105.24K | -35.17K | -206.94K | 359.35K | 423.35K | 739.19K | 843.98K | 30.46K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -283.73% | -639.70% | 42.37% | 59.27% | 50.00% | 99.00% | 100.00% | 86.30% | 84.94% | -9.80% | -61.34% | 50.12% | 37.31% | 38.85% | 45.68% | 100.00% |
| Research & Development | 1.05M | 1.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 753.02K | 1.50M | 510.85K | 0.00 | 0.00 | 225.57K | 294.74K | 549.76K | 723.29K | 1.37M | 2.22M | 1.58M | 2.15M | 1.61M | 1.37M | 1.04M |
| General & Administrative | 1.58M | 2.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.58M | 2.05M | 734.06K | 1.05M | 1.22M | 1.58M | 1.44M | 1.66M | 1.38M | 1.99M | 3.71M | 6.53M | 8.56M | 6.96M | 7.56M | 4.15M | 2.60M | 1.25M | 1.82M | 2.71M | 2.59M | 1.35M | 2.02M | 2.47M | 1.72M | 1.37M |
| Other Expenses | 343.00K | 0.00 | 0.00 | 3.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 235.90K | 836.40K | 7.52M | 1.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 367.40K | 0.00 | 0.00 | 612.33K | 0.00 |
| Operating Expenses | 2.63M | 3.50M | 734.06K | 1.05M | 1.22M | 1.58M | 1.44M | 1.66M | 1.38M | 1.99M | 4.47M | 8.03M | 9.31M | 7.80M | 15.08M | 6.29M | 2.90M | 1.80M | 2.55M | 4.08M | 4.81M | 3.30M | 4.16M | 4.08M | 3.70M | 2.41M |
| Cost & Expenses | 2.63M | 3.50M | 734.06K | 1.05M | 1.22M | 1.58M | 1.44M | 1.66M | 1.38M | 1.99M | 6.26M | 12.24M | 12.39M | 9.31M | 15.40M | 6.40M | 2.90M | 1.81M | 2.56M | 4.47M | 5.35M | 3.66M | 4.88M | 5.24M | 4.71M | 2.41M |
| Interest Income | 33.00 | 36.00 | 28.71K | 26.67K | 18.15K | 14.57K | 10.08K | 5.83K | 17.49K | 18.15K | 109.25K | 154.48K | 346.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 151.58K | 160.15K | 62.80K | 212.08K | -1.17M | -312.27K | 98.60K | -198.88K | -2.75M | 1.02M | 20.81K | 80.57K | 66.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.48M | 498.60K | 2.59M | 383.20K | 0.00 |
| Depreciation & Amortization | 343.03K | 160.15K | 489.00 | 763.00 | 826.00 | 1.30K | 2.05K | 2.30K | 2.59K | 3.19K | 277.16K | 602.23K | 733.00K | 50.71K | 64.86K | 59.42K | 94.35K | 135.45K | 258.92K | 285.76K | 260.32K | 367.40K | 354.64K | 341.07K | 836.69K | 738.65K |
| EBITDA | -2.28M | -3.50M | -733.57K | -1.05M | -1.22M | -1.58M | -1.44M | -1.66M | -1.65M | -3.80M | -4.81M | -6.45M | 3.74M | -4.86M | -6.70M | 8.79M | 142.58K | -1.63M | -2.18M | -3.83M | -4.75M | 1.91M | -2.89M | -406.06K | -1.65M | -1.64M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,026.11% | -1,135.62% | 69.93% | -131.12% | -1,049.65% | 85.26% | 4.78% | -2,135.74% | -1,760.27% | -1,067.54% | -1,408.97% | 266.71% | -254.54% | -21.34% | -89.22% | -5,383.37% |
| Operating Income | -2.63M | -3.66M | -734.06K | -1.05M | -1.22M | -1.58M | -1.44M | -1.66M | -1.38M | -1.99M | -6.44M | -12.76M | -7.04M | -5.60M | -14.76M | 3.91M | 87.42K | -1.74M | -2.44M | -4.12M | -5.01M | -2.94M | -3.74M | -3.34M | -2.86M | -2.38M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,373.87% | -2,247.45% | -131.47% | -151.11% | -2,311.24% | 37.94% | 2.93% | -2,273.54% | -1,969.24% | -1,147.18% | -1,486.13% | -410.08% | -329.74% | -175.50% | -154.81% | -7,808.68% |
| Total Other Income/Expenses | 249.05K | -20.80K | -91.51K | -238.75K | 1.16M | 297.70K | -106.86K | 104.33K | 2.45M | -1.48M | 429.75K | 985.65K | 8.84M | 19.23M | 40.97M | 23.03M | 39.20K | 30.15K | 0.00 | -1.37M | 0.00 | -4.48M | -498.60K | -2.59M | -375.00K | 0.00 |
| Income Before Tax | -2.38M | -3.68M | -796.86K | -1.26M | -42.97K | -1.26M | -1.53M | -1.55M | 1.08M | -3.46M | -5.28M | -10.61M | 2.08M | 15.93M | 34.45M | 31.76M | 87.42K | -1.71M | 0.00 | -5.49M | 0.00 | -2.94M | -4.24M | -5.93M | -3.24M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,126.12% | -1,867.85% | 38.77% | 429.58% | 5,392.47% | 308.06% | 2.93% | -2,234.09% | 0.00% | -1,529.24% | 0.00% | -410.08% | -373.69% | -311.74% | -175.56% | 0.00% |
| Income Tax Expense | 2.40K | 2.40K | 1.60K | -49.76K | 2.40K | 2.40K | 1.57K | 6.00K | -113.00 | -875.00 | 6.24M | -3.93M | 964.13K | 6.43M | 10.76M | -19.94M | 2.74M | 2.38M | 1.45M | 1.37M | -45.05K | 9.03M | 1.03M | 5.15M | -1.02M | 0.00 |
| Net Income | -2.38M | -3.68M | -798.46K | -1.21M | -45.37K | -1.27M | -1.54M | -1.47M | 1.10M | -4.82M | -11.52M | -6.68M | 881.51K | 9.39M | 23.69M | 28.67M | -2.69M | -4.15M | -3.89M | -5.49M | -4.97M | -7.49M | -4.28M | -5.89M | -1.46M | -2.38M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,456.99% | -1,176.16% | 16.46% | 253.18% | 3,708.79% | 278.11% | -90.31% | -5,430.70% | -3,138.18% | -1,529.24% | -1,472.77% | -1,044.51% | -376.93% | -309.78% | -79.23% | -7,808.68% |
| EPS | -0.33 | -0.55 | -1.00 | -1.52 | -0.06 | -1.59 | -1.93 | -1.83 | 1.36 | -5.97 | -14.21 | -8.21 | 1.09 | 10.00 | 30.00 | 45.00 | -6.05 | -14.85 | -20.73 | -41.06 | -46.50 | -84.80 | -55.00 | -95.03 | -26.92 | -51.01 |
| EPS Diluted | -0.33 | -0.55 | -1.00 | -1.52 | -0.06 | -1.59 | -1.93 | -1.83 | 1.35 | -5.97 | -14.21 | -8.21 | 1.09 | 10.00 | 30.00 | 35.00 | -6.05 | -14.85 | -20.73 | -41.06 | -46.50 | -84.80 | -55.00 | -95.03 | -26.92 | -51.01 |
| Weighted Avg Shares Out | 7.24M | 6.71M | 797.10K | 797.10K | 797.10K | 797.10K | 797.10K | 802.90K | 805.05K | 807.25K | 810.51K | 814.10K | 806.20K | 781.91K | 756.07K | 632.20K | 444.99K | 279.53K | 187.58K | 133.62K | 106.87K | 88.31K | 77.75K | 62.03K | 54.38K | 46.62K |
| Weighted Avg Shares Out (Dil) | 7.24M | 6.71M | 797.10K | 797.10K | 797.10K | 797.10K | 797.10K | 802.90K | 810.85K | 807.25K | 810.51K | 814.10K | 811.71K | 794.97K | 827.20K | 825.93K | 444.99K | 279.53K | 187.58K | 133.62K | 106.87K | 88.31K | 77.75K | 62.03K | 54.38K | 46.62K |
Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.
- The clinical assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and access to Oncotelic's AI platform for identifying immunotherapy combinations HUNTINGTON BEACH, CA / ACCESSWIRE / April 29, 2024 / Mosaic ImmunoEngineering,...
Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego
- Nanoparticle-based technology complements the company's intratumoral technology platform - NOVATO, CA / ACCESSWIRE / October 6, 2021 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel...
Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering's Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates
NOVATO, CA / ACCESSWIRE / October 1, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, today...
Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology
- Presentation highlighted potential of polymer-based delivery system for slow-release of vaccines that potentially require no booster shots - - Delivery system is transportation and storage friendly with no refrigeration or freezing requirements - NOVATO, CA / ACCESSWIRE / September...
Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of Its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform
Vaccine candidates triggered high production of neutralizing antibodies against SARS-CoV-2 and SARS-CoV-1 in preclinical studies Epitopes used in the vaccine candidates are located in regions that are not known to be susceptible to mutations, including the SARS-CoV-2 Delta Variant The...
Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego
- Licensed Candidates Hold Potential to Address Emerging SARS-CoV-2 and other Infectious Diseases Including Human and Veterinary Applications - - Data Supporting the Potential of Lead Vaccine Candidates was Funded Through Competitive Federal Grants and has Been Published in Peer...
Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering's Lead Intratumoral Immunotherapy Candidate, MIE-101
- Results Demonstrate Innate Immune System Activation Through Stimulation of Three Toll-Like Receptors (TLRs 2,4,7) - - MIE-101 Therapy Reduced Tumor Growth by 80% Compared to Tumors Treated with Agents Targeting TLRs 2 and 4 or TLR 7 Alone -...
Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting
NOVATO, CA / ACCESSWIRE / June 28, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused onimmunotherapies to treat and prevent cancer and infectious diseases through innate and adaptive immune activation, announced today that...
Source: https://incomestatements.info
Category: Stock Reports